Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis
Open Access
- 1 March 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (3), 581-595
- https://doi.org/10.1093/jac/dkx431
Abstract
Atovaquone/proguanil, registered as Malarone(A (R)), is a fixed-dose combination recommended for first-line treatment of uncomplicated Plasmodium falciparum malaria in non-endemic countries and its prevention in travellers. Mutations in the cytochrome bc(1) complex are causally associated with atovaquone resistance. This systematic review assesses the clinical efficacy of atovaquone/proguanil treatment of uncomplicated malaria and examines the extent to which codon 268 mutation in cytochrome b influences treatment failure and recrudescence based on published information. Data suggest that atovaquone/proguanil treatment efficacy is 89%-98% for P. falciparum malaria (from 27 studies including between 18 and 253 patients in each case) and 20%-26% for Plasmodium vivax malaria (from 1 study including 25 patients). The in vitro P. falciparum phenotype of atovaquone resistance is an IC50 value > 28 nM. Case report analyses predict that recrudescence in a patient presenting with parasites carrying cytochrome b codon 268 mutation will occur on average at day 29 (95% CI: 22, 35), 19 (95% CI: 7, 30) days longer than if the mutation is absent. Evidence suggests atovaquone/proguanil treatment for P. falciparum malaria is effective. Late treatment failure is likely to be associated with a codon 268 mutation in cytochrome b, though recent evidence from animal models suggests these mutations may not spread within the population. However, early treatment failure is likely to arise through alternative mechanisms, requiring further investigation.Keywords
Funding Information
- Wellcome Trust (204809/Z/16/Z)
- European Union Seventh Framework Programme (304948—NanoMal)
This publication has 72 references indexed in Scilit:
- Therapy of uncomplicated falciparum malaria in Europe: MALTHER – a prospective observational multicentre studyMalaria Journal, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- A thirteen-year analysis of Plasmodium falciparum populations reveals high conservation of the mutant pfcrt haplotype despite the withdrawal of chloroquine from national treatment guidelines in GabonMalaria Journal, 2011
- Towards an In Vitro Model of Plasmodium Hypnozoites Suitable for Drug DiscoveryPLOS ONE, 2011
- Dynamics of Malaria Drug Resistance Patterns in the Amazon Basin Region following Changes in Peruvian National Treatment Policy for Uncomplicated MalariaAntimicrobial Agents and Chemotherapy, 2009
- Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanilMalaria Journal, 2008
- Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trialMalaria Journal, 2008
- First Case of Emergence of Atovaquone-Proguanil Resistance in Plasmodium falciparum during Treatment in a Traveler in ComorosAntimicrobial Agents and Chemotherapy, 2008
- In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of ThailandMalaria Journal, 2008
- First Case of Emergence of Atovaquone Resistance in Plasmodium falciparum during Second-Line Atovaquone-Proguanil Treatment in South AmericaAntimicrobial Agents and Chemotherapy, 2007